CAR therapies
Israeli Oncologists Show Point-of-Care CAR T Cells Have Comparable Efficacy to Yescarta, Kymriah
Premium
Lymphoma patients better tolerated the CAR T-cell therapy manufactured on-site at the Sheba Medical Center than they did the commercially available options.
'Fresh-In, Fresh-Out' Dual-Targeted CAR T-Cell Therapy Shows Promise in Phase II DLBCL Trial
Premium
The non-cryopreserved CD19- and CD20-directed CAR T-cell therapy zamto-cel is manufactured in a closed-system device that could enable point-of-care treatment.
Senti Biosciences Announces $37.6M PIPE Financing, Reports Early Data From Phase I CAR-NK Trial
The firm plans to put the proceeds toward further developing its cell therapy in CD33- or FLT3-expressing AML and for other R&D activities.
Despite Overall Survival Miss, Singapore Researchers Champion Success of Global Cell Therapy Trial
Premium
The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell therapy to date.
In Brief This Week: Hemogenyx, Intellia, Care Access
News items for the week of Nov. 25, 2024.
Oct 15, 2024